NCT06415903View on ClinicalTrials.gov

A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

August 31, 2026

Conditions
Advanced Malignant Cancer
Interventions
DRUG

TQB3117 tablets

TQB3117 is a protein inhibitor.

Trial Locations (1)

250117

The First Affiliated Hospital of Shandong First Medical University, Jinan

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY